Recurrent cervical carcinoma Trials in Oklahoma City, United States
Conditions / Recurrent cervical carcinoma / Oklahoma City, United States
Recurrent cervical carcinoma has been the subject of sustained clinical investigation across multiple research sites.
12 total trials for this combination
Showing top 10 of 12 trials
Trials
| NCT ID | Title | Status | Phase |
|---|---|---|---|
| NCT02465060 | Targeted Therapy Directed by Genetic Testing in Treating Patients With Advanced Refractory Solid Tumors, Lymphomas, or Multiple Myeloma (The MATCH Screening Trial) | ACTIVE_NOT_RECRUITING | — |
| NCT02465060 | Targeted Therapy Directed by Genetic Testing in Treating Patients With Advanced Refractory Solid Tumors, Lymphomas, or Multiple Myeloma (The MATCH Screening Trial) | ACTIVE_NOT_RECRUITING | — |
| NCT00897442 | Collecting Tumor Samples From Patients With Gynecological Tumors | COMPLETED | — |
| NCT01098630 | Patient, Physician, and Nurse Factors Associated With Entry Onto Clinical Trials and Finishing Treatment in Patients With Primary or Recurrent Uterine, Endometrial, or Cervical Cancer | COMPLETED | — |
| NCT02465060 | Targeted Therapy Directed by Genetic Testing in Treating Patients With Advanced Refractory Solid Tumors, Lymphomas, or Multiple Myeloma (The MATCH Screening Trial) | ACTIVE_NOT_RECRUITING | — |
| NCT00803062 | Paclitaxel and Cisplatin or Topotecan With or Without Bevacizumab in Treating Patients With Stage IVB, Recurrent, or Persistent Cervical Cancer | COMPLETED | PHASE3 |
| NCT02465060 | Targeted Therapy Directed by Genetic Testing in Treating Patients With Advanced Refractory Solid Tumors, Lymphomas, or Multiple Myeloma (The MATCH Screening Trial) | ACTIVE_NOT_RECRUITING | — |
| NCT02257528 | Nivolumab in Treating Patients With Persistent, Recurrent, or Metastatic Cervical Cancer | ACTIVE_NOT_RECRUITING | — |
| NCT01266447 | Veliparib, Topotecan Hydrochloride, and Filgrastim or Pegfilgrastim in Treating Patients With Persistent or Recurrent Cervical Cancer | COMPLETED | PHASE2 |
| NCT01281852 | Paclitaxel, Cisplatin, and Veliparib in Treating Patients With Advanced, Persistent, or Recurrent Cervical Cancer | COMPLETED | PHASE1 |